Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Abstract Text:

Ankur Sharma,Clay E S Comstock,Erik S Knudsen,Khanh H Cao,Janet K Hess-Wilson,Lisa M Morey,Jason Barrera,Karen E Knudsen,

The retinoblastoma tumor suppressor protein (RB), a critical mediator of cell cycle progression, is functionally inactivated in the majority of human cancers, including prostatic adenocarcinoma. The importance of RB tumor suppressor function in this disease is evident because 25% to 50% of prostatic adenocarcinomas harbor aberrations in RB pathway. However, no previous studies challenged the consequence of RB inactivation on tumor cell proliferation or therapeutic response. Here, we show that RB depletion facilitates deregulation of specific E2F target genes, but does not confer a significant proliferative advantage in the presence of androgen. However, RB-deficient cells failed to elicit a cytostatic response (compared with RB proficient isogenic controls) when challenged with androgen ablation, AR antagonist, or combined androgen blockade. These data indicate that RB deficiency can facilitate bypass of first-line hormonal therapies used to treat prostate cancer. Given the established effect of RB on DNA damage checkpoints, these studies were then extended to determine the impact of RB depletion on the response to cytotoxic agents used to treat advanced disease. In this context, RB-deficient prostate cancer cells showed enhanced susceptibility to cell death induced by only a selected subset of cytotoxic agents (antimicrotubule agents and a topoisomerase inhibitor). Combined, these data indicate that RB depletion dramatically alters the cellular response to therapeutic intervention in prostate cancer cells and suggest that RB status could potentially be developed as a marker for effectively directing therapy.

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Publishing Authors By Initials

A Sharma,CE Comstock,ES Knudsen,KH Cao,JK Hess-Wilson,LM Morey,J Barrera,KE Knudsen,

For similar investigative techniques: genetic techniques: gene transfer techniques: transfection research abstracts see: investigative techniques: genetic techniques: gene transfer techniques: transfection research

PUBMED ID PMID:

MEDLINE DATE:

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cancer research

VOLUME: 67

Page Numbers: 6192-203

Journal Abbreviation: Cancer Res.

ISSN: 0008-5472

DAY: 1

MONTH: Jul

YEAR: 2007

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Keywords Mesh Terms:

KEYWORDS: Transfection

MESH TERMS: physiology

Chemical & Substance for Abstract: Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Information

Substance Name: Bromodeoxyuridine

Registry Number: 59-14-3

Grant and Affiliation Information for Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

AFFILIATION: Department of Cell and Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0521, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA116777

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells Related Publications

• Age Modifies the Pituitary TSH Response to Thyroid Failure.
• Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer.
• Discourses of agency and the search for the authentic self: The case of mood-modifying medicines.
• Gingival epithelial cells heterozygous for Toll-like receptor 4 polymorphisms Asp299Gly and Thr399ile are hypo-responsive to Porphyromonas gingivalis.
• Impact of differential cyclin D1 expression and localisation in prostate cancer.
• Improved parameter estimation for systems with an experimentally located Hopf bifurcation.
• Integrative database management for mouse development: systems and concepts.
• Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics.
• Migrating with myosin VI.
• Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult.
• Neuroimaging of the serotonin reuptake site requires high-affinity ligands.
• Patterns of organization and management in private and public substance abuse treatment programs.
• Phototoxic furanocoumarins.
• Placental perfusion - a human alternative.
• Psychiatry and torture.
• RB activity alters checkpoint response and chemosensitivity in lung cancer lines.
• RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis.
• RB loss promotes aberrant ploidy by deregulating levels and activity of DNA replication factors.
• Regulation of cell proliferation in a stratified culture system of epithelial cells from prostate tissue.
• Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.
• Reprogramming of genetic networks during initiation of the Fetal Alcohol Syndrome.
• Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
• SWI/SNF activity is required for the repression of deoxyribonucleotide triphosphate metabolic enzymes via the recruitment of mSin3B.
• Saint Lucia revisited.
• The human placenta - An alternative for studying foetal exposure.
• Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal.
• Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
• Variability of estimated binding parameters.
• [Not Available.]
• [Not Available.]